Items where Author is "Boz, C."

Article

(2026) Comparative effectiveness of ocrelizumab in subgroups of patients with multiple sclerosis: a multi-registry observational cohort study. Journal of Neurology Neurosurgery and Psychiatry. pp. 763-773. ISSN 0022-3050

(2026) Effect of late-onset on multiple sclerosis phenotype and outcome: evidence from a multi-national registry. Journal of Neurology. p. 15. ISSN 0340-5354

(2026) Impact of Age at Onset on Relapse and Disability in AQP4-IgG Neuromyelitis Optica Spectrum Disorder. Neurology. p. 12. ISSN 0028-3878

(2026) Preserving Neurological Function in People at High and Low Risk of Aggressive Multiple Sclerosis: An Observational Cohort Study. Cns Drugs. pp. 1011-1025. ISSN 1172-7047

(2025) Disease course after pregnancy in women with progressive multiple sclerosis symptoms. Multiple Sclerosis Journal. pp. 1439-1451. ISSN 1352-4585

(2025) First-year treatment response predicts the following 5-year disease course in patients with relapsing-remitting multiple sclerosis. Neurotherapeutics. p. 12. ISSN 1933-7213

(2025) Four years on: Pregnancy and birth outcomes reported in the MSBase pregnancy, neonatal outcomes, and Women's Health Registry (2020-2024). Multiple Sclerosis Journal. pp. 1088-1101. ISSN 1352-4585

(2025) Moderate-high efficacy disease-modifying therapies reduce relapse risk in late-onset multiple sclerosis. Journal of neurology, neurosurgery, and psychiatry. pp. 50-58. ISSN 1468-330X (Electronic) 0022-3050 (Linking)

(2025) Progression independent of relapse activity and relapse-associated worsening in seronegative NMOSD: an international cohort study. Journal of Neurology. p. 339. ISSN 1432-1459 (Electronic) 0340-5354 (Print) 0340-5354 (Linking)

(2024) Comparative Effectiveness of Natalizumab, Fingolimod, and Injectable Therapies in Pediatric-Onset Multiple Sclerosis A Registry-Based Study. Neurology. p. 12. ISSN 0028-3878

(2024) Comparative effectiveness of dimethyl fumarate versus non-specific immunosuppressants: Real-world evidence from MSBase. Multiple Sclerosis Journal-Experimental Translational and Clinical. p. 13.

(2024) Disease Activity in Pregnant and Postpartum Women with Multiple Sclerosis Receiving Ocrelizumab or Other Disease-Modifying Therapies. Neurology: Neuroimmunology and NeuroInflammation. ISSN 23327812 (ISSN)

(2024) How patients with neuromyelitis optica spectrum disorder accumulate disability. Multiple Sclerosis Journal. pp. 1158-1160. ISSN 1352-4585

(2024) Preserving neurological function in patients at high risk and low risk of aggressive MS. Multiple Sclerosis Journal. pp. 631-634. ISSN 1352-4585

(2024) Prevalence of Progression Independent of Relapse Activity and Relapse-Associated Worsening in Patients With AQP4-IgG-Positive NMOSD. Neurology. e209940. ISSN 1526-632X (Electronic) 0028-3878 (Linking)

(2024) A standardised definition of progression independent of relapse activity in multiple sclerosis. Multiple Sclerosis Journal. pp. 442-445. ISSN 1352-4585

(2023) Comparative effectiveness in multiple sclerosis: A methodological comparison. Multiple Sclerosis Journal. pp. 326-332. ISSN 1352-4585

(2023) Disability accrual in primary and secondary progressive multiple sclerosis. Journal of Neurology Neurosurgery and Psychiatry. pp. 707-717. ISSN 0022-3050

(2023) Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal. pp. 875-883. ISSN 1352-4585

(2023) Effect of high-efficacy therapy on the course of disability in paediatric-onset multiple sclerosis. Multiple Sclerosis Journal. pp. 103-105. ISSN 1352-4585

(2023) Effectiveness of multiple disease-modifying therapies in relapsing-remitting multiple sclerosis: causal inference to emulate a multiarm randomised trial. Journal of Neurology Neurosurgery and Psychiatry. pp. 1004-1011. ISSN 0022-3050

(2023) External validation of a clinical prediction model in multiple sclerosis. Multiple sclerosis (Houndmills, Basingstoke, England). pp. 261-269. ISSN 1477-0970 (Electronic) 1352-4585 (Linking)

(2023) A Multi-Country Comparative Effectiveness Study of Dimethyl Fumarate and Non-Specific Immunosuppressants in a Real-World Setting: Evidence from MSBase. Multiple Sclerosis Journal. NP29-NP30. ISSN 1352-4585

(2023) Variability of the response to immunotherapy among subgroups of patients with multiple sclerosis. European Journal of Neurology. pp. 1014-1024. ISSN 1351-5101

(2022) Association of Latitude and Exposure to Ultraviolet B Radiation With Severity of Multiple Sclerosis An International Registry Study. NEUROLOGY. E2401-E2412. ISSN 0028-3878 1526-632X J9 - NEUROLOGY

(2022) Association of Latitude and Exposure to Ultraviolet B Radiation With Severity of Multiple Sclerosis: An International Registry Study. Neurology. e2401-e2412. ISSN 1526-632X (Electronic) 0028-3878 (Print) 0028-3878 (Linking)

(2022) Confirmed disability progression as a marker of permanent disability in multiple sclerosis. European Journal of Neurology. pp. 2321-2334. ISSN 13515101 (ISSN)

(2022) Confirmed disability progression as a marker of permanent disability in multiple sclerosis. EUROPEAN JOURNAL OF NEUROLOGY. pp. 2321-2334. ISSN 1351-5101 1468-1331 J9 - EUR J NEUROL

(2022) Description of Multiple Sclerosis cohorts from the Middle East between 2009 and 2019. Multiple Sclerosis Journal. pp. 17-18. ISSN 1352-4585

(2022) Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple Sclerosis. NEUROLOGY. ISSN 0028-3878

(2022) Impact of methodological choices in comparative effectiveness studies: application in natalizumab versus fingolimod comparison among patients with multiple sclerosis. BMC MEDICAL RESEARCH METHODOLOGY. ISSN 1471-2288 J9 - BMC MED RES METHODOL

(2022) Impact of methodological choices in comparative effectiveness studies: application in natalizumab versus fingolimod comparison among patients with multiple sclerosis. Bmc Medical Research Methodology. p. 14.

(2022) Multiple Sclerosis Severity Score (MSSS) improves the accuracy of individualized prediction in MS. Mult Scler. p. 13524585221084577. ISSN 1352-4585

(2022) The risk of secondary progressive multiple sclerosis is geographically determined but modifiable. Multiple Sclerosis Journal. pp. 967-970. ISSN 1352-4585

(2021) Disability outcomes of early cerebellar and brainstem symptoms in multiple sclerosis. Multiple Sclerosis Journal. pp. 755-766. ISSN 1352-4585

(2021) Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years. Neurology. E783-E797. ISSN 0028-3878

(2021) Longitudinal machine learning modeling of MS patient trajectories improves predictions of disability progression. Comput Methods Programs Biomed. p. 106180. ISSN 0169-2607

(2021) Utilization of Multiple Sclerosis Therapies in the Middle East Over a Decade: 2009-2018. CNS Drugs. ISSN 1172-7047

(2021) The effectiveness of natalizumab vs fingolimod-A comparison of international registry studies. Mult Scler Relat Disord. p. 103012. ISSN 2211-0348

(2020) Immune Reconstitution Therapy or Continuous Immunosuppression for the Management of Active Relapsing-Remitting Multiple Sclerosis Patients? A Narrative Review. Neurology and Therapy. pp. 55-66. ISSN 2193-8253

(2019) Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis. Jama-Journal of the American Medical Association. pp. 175-187. ISSN 0098-7484

(2019) Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis. J Neurol Neurosurg Psychiatry. pp. 458-468. ISSN 1468-330X (Electronic) 0022-3050 (Linking)

(2018) Association of Inflammation and Disability Accrual in Patients With Progressive-Onset Multiple Sclerosis. JAMA Neurol. pp. 1407-1415. ISSN 2168-6157 (Electronic) 2168-6149 (Linking)

(2018) Disability outcomes in patients with early cerebellar symptoms in multiple sclerosis. Multiple Sclerosis Journal. pp. 135-137. ISSN 1352-4585

(2018) Long-term disability trajectories in primary progressive MS patients: A latent class growth analysis. Multiple sclerosis (Houndmills, Basingstoke, England). pp. 642-652. ISSN 1477-0970 (Electronic) 1352-4585 (Linking)

(2018) Presentation of Neuromyelitis Optica (NMO) in patients from different racial groups: analysis of the global NMOBase Registry. Neurology. ISSN 0028-3878

(2017) Contribution of different relapse phenotypes to disability in multiple sclerosis. Multiple Sclerosis Journal. pp. 266-276. ISSN 1352-4585

(2017) Contribution of inflammation to disability accrual in primary progressive multiple sclerosis. Multiple Sclerosis Journal. pp. 399-401. ISSN 1352-4585

(2017) Disease modifying therapy improves disability outcomes in relapsing-remitting multiple sclerosis over 22 years. Multiple Sclerosis Journal. pp. 361-363. ISSN 1352-4585

(2017) Prognostic Indicators in Pediatric Clinically Isolated Syndrome. Annals of Neurology. pp. 729-739. ISSN 0364-5134

(2017) Timing of high-efficacy disease modifying therapies for relapsing-remitting multiple sclerosis. Multiple Sclerosis Journal. pp. 71-73. ISSN 1352-4585

(2017) Towards personalized therapy for multiple sclerosis: prediction of individual treatment response. Brain. pp. 2426-2443. ISSN 0006-8950

(2016) Early disease modifying treatment delays disability accumulation in patients with pediatric onset clinically isolated syndrome suggestive of multiple sclerosis. Multiple Sclerosis Journal. pp. 62-63. ISSN 1352-4585

(2016) Individual response to disease modifying therapies: a global observational cohort study. Multiple Sclerosis Journal. pp. 358-360. ISSN 1352-4585

(2016) Long-term disability trajectories in primary progressivs MS patients - a latent class growth analysis. Multiple Sclerosis Journal. pp. 44-46. ISSN 1352-4585

(2015) BREMSO: a simple score to predict early the natural course of multiple sclerosis. European Journal of Neurology. pp. 981-989. ISSN 1351-5101

(2015) Male Sex Is Independently Associated with Faster Disability Accumulation in Relapse-Onset MS but Not in Primary Progressive MS. Plos One. ISSN 1932-6203